-
What Can China Teach Us About CAR-T?
What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China -
Staying the Course
Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index, -
Cell and Gene Therapies: The Path to Commercialization
Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet -
Bridges and Barriers to Advancing CAR T Therapy
One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In
Our Medical Affairs executive services help BioPharmaceutical companies strategically plan, organize and operate with greater efficiency. Therefore, maximizing the value of their Medical Affairs function.
Service lines include:
Click the Tabs Below for Case Studies, White Papers, and Articles
-
Portfolio Optimization
Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of -
Portfolio Prioritization – Oncology
Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. -
Oncology Commercial Assessment – Melanoma
Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the -
Product Search
Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and -
Commercial Assessment
Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment -
Business Development and Licensing
Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with
-
Growth by Acquisition in Life Sciences: Do You Have a Plan?
Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as -
R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation
James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation? -
Merck KGaA and Bayer Choose Opposite Strategies
Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent -
Foundation Medicine and Clovis Expand Partnership
Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion -
Role of Companion Diagnostics in Immuno-oncology Race Unfolding
Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies -
Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity
Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its